The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet-Reference-Cited by-同舟云学术

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet

Published:2022-05 Issue:5 Volume:7 Page:1084-1092
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Scholtes Rosalie A.^ORCID,Muskiet Marcel H.A.,van Baar Michiel J.B.,Hesp Anne C.,Greasley Peter J.,Hammarstedt Ann,Karlsson Cecilia,Hallow Karen M.,Danser A.H. Jan,Heerspink Hiddo J.L.^ORCID,van Raalte Daniël H.

Publisher

Elsevier BV

Subject

Nephrology

Reference38 articles.

1. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome;van Bommel;Clin J Am Soc Nephrol,2017

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lithium in Drinking Water and its Potential Impact on Mental Health: A Review;Current Medicinal Chemistry;2024-07-10

2. Sodium–Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction;Diagnostics;2024-06-05

3. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF;JACC: Heart Failure;2024-01

4. Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial;Frontiers in Medicine;2023-12-14

5. Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus;Pharmaceutics;2023-10-25